Surveillance of hepatocellular carcinoma in patients with hepatitis C virus infection may improve patient survival

Liver Int. 2006 Jun;26(5):543-51. doi: 10.1111/j.1478-3231.2006.01270.x.

Abstract

Background: The benefit of surveillance of hepatocellular carcinoma (HCC) for patients with hepatitis C virus (HCV) infection, in terms of long-term survival, has not yet been established.

Methods: A total of 384 consecutive anti-HCV-positive HCC patients admitted to our hospital between January 1991 and October 2003 were enrolled. Patients were categorized into two groups, a surveillance group (182 patients) and a non-surveillance group (202 patients), according to tumor detection in a surveillance program based on periodical examination via ultrasound sonography and alpha fetoprotein determination at 6-month intervals, and their survival rates were compared.

Results: Although there were no significant differences in age and Child-Pugh classes between the two groups, the surveillance group exhibited a smaller tumor size (19 vs. 35 mm) and a higher incidence of single HCC (67% vs. 46%), compared with the non-surveillance group (each, P < 0.001). The cumulative survival rate in the surveillance group was higher than that in the non-surveillance group (5 years survival, 46% vs. 32%, P < 0.001). When the survival after correction of the lead-time bias in the surveillance group was analyzed according to the Child-Pugh classification, the surveillance program was found to have had a favorable outcome in Child-Pugh class A patients, but not in Child-Pugh class B/C patients.

Conclusions: HCC surveillance for patients with HCV infection can lead to discovery of tumors at an early stage, especially in Child-Pugh class A, resulting in a favorable outcome.

Publication types

  • Comparative Study

MeSH terms

  • ADAM Proteins / therapeutic use
  • ADAM17 Protein
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / mortality*
  • Carcinoma, Hepatocellular / virology
  • Female
  • Follow-Up Studies
  • Hepatitis C / complications*
  • Hepatitis C / drug therapy
  • Hepatitis C / mortality
  • Humans
  • Male
  • Middle Aged
  • Population Surveillance*
  • Retrospective Studies
  • Survival Rate
  • Tumor Burden

Substances

  • Antineoplastic Agents
  • ADAM Proteins
  • ADAM17 Protein